Clinical Trial Update: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy [Phase 2, Phase 3]

View source ↗

Summary

An oral paclitaxel trial for first-line treatment of recurrent or metastatic breast cancer is in Phase 2/3 and currently not recruiting. Sponsored by Daehwa Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• paclitaxel (oral) (paclitaxel)

Snippet

Sponsor: Daehwa Pharmaceutical Co., Ltd. | Conditions: Recurrent or Metastatic Breast Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING